<DOC>
	<DOCNO>NCT00385255</DOCNO>
	<brief_summary>The current study provide information use Boostrix concomitantly influenza vaccine adult age 19-64 year . This study also provide safety immunogenicity data cohort adult age great equal 65 year .</brief_summary>
	<brief_title>Immunogenicity , Safety GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix Adults</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Healthy male female adult age 19 64 year , inclusive primary cohort ) , age 65 year old ( exploratory cohort ) , time vaccination . Administration influenza vaccine within six month prior study entry Administration diphtheriatetanus ( Td ) booster within previous 5 year . Administration Tdap vaccine time prior study entry . Administration investigational nonregistered drug vaccine study vaccine within 30 day precede vaccination , plan use entire study period . History diphtheria and/or tetanus and/or pertussis disease . History serious allergic reaction ( e.g . anaphylaxis ) follow tetanus toxoid , diphtheria toxoid pertussiscontaining vaccine influenza vaccine component study vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Immunogenicity ,</keyword>
	<keyword>Influenza</keyword>
	<keyword>Co-administration ,</keyword>
	<keyword>Tdap ,</keyword>
</DOC>